--- title: "Pre-market hot trades in US stocks: Linde pre-market down 3.26%; KLA pre-market up 3.19%" type: "News" locale: "en" url: "https://longbridge.com/en/news/294516298.md" description: "Linde pre-market down 3.26%; KLA pre-market up 3.19%; Focus Media pre-market up 334.04%; Microbus pre-market up 304.33%; Replimune pre-market up 129.69%" datetime: "2026-07-31T12:53:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294516298.md) - [en](https://longbridge.com/en/news/294516298.md) - [zh-HK](https://longbridge.com/zh-HK/news/294516298.md) --- # Pre-market hot trades in US stocks: Linde pre-market down 3.26%; KLA pre-market up 3.19% **Hot Pre-Market Trades in U.S. Stocks** Linde is down 3.26% in pre-market trading. Based on recent key news: 1. On July 31, Linde announced a long-term agreement with one of the world's largest semiconductor manufacturers to supply ultra-high purity industrial gases and will invest approximately $1 billion to expand its facilities in Arizona. This news highlights Linde's growth potential in the semiconductor industry, but investors are concerned about the increase in capital expenditures in the short term, leading to a decline in stock price. 2. On July 31, Linde released its second-quarter financial report, with adjusted earnings per share of $4.50, a year-on-year increase of 10%, exceeding market expectations. However, despite strong performance, the market remains skeptical about the sustainability of future earnings growth, affecting stock performance. 3. On July 31, Linde raised its full-year adjusted earnings per share forecast to $17.70 to $17.90, slightly above the previous guidance lower limit. This adjustment reflects the company's confidence in future performance, but the market remains cautious due to uncertainties in the macroeconomic environment. Semiconductor demand is growing, but the macro environment is uncertain. KLA is up 3.19% in pre-market trading. Based on recent key news: 1. On July 30, KLA announced its fourth-quarter results for fiscal year 2026, with revenue reaching $3.66 billion, a record high, and net profit of $1.363 billion, a year-on-year increase of 13%. However, the guidance for the first fiscal quarter did not meet market expectations, raising investor concerns about the peak of the semiconductor cycle. Morgan Stanley raised KLA's target price from $200 to $238, maintaining an "Overweight" rating. Analysts believe that despite cautious short-term guidance, demand for artificial intelligence and advanced packaging will drive accelerated growth in the second half of fiscal year 2027. 2. On July 29, KLA reported its fourth-quarter financial results for fiscal year 2026 and the guidance for the next quarter, both of which exceeded Wall Street expectations, but the stock price fell in after-hours trading. The financial report showed a year-on-year revenue increase of 15% to $3.66 billion, surpassing analysts' expectations of $3.6 billion; adjusted earnings per share were $1.05, also higher than the market expectation of $1.00. Despite exceeding expectations in both performance and guidance, the stock price fell sharply in after-hours trading, possibly reflecting investor concerns about the semiconductor equipment industry's cycle peaking or disappointment over the modest extent of the guidance beat. 3. On July 29, KLA updated its business portfolio expectations, indicating that among the revenue from process control systems related to semiconductor customers, foundry and logic customers account for about 73%, while memory accounts for about 27%; within the memory business, DRAM accounts for about 90%, and NAND accounts for about 10%. KLA expects that by the end of the fiscal year 2026, the order backlog will reach approximately $12.5 billion and is optimistic that operational growth in the second half of 2026 will improve by about 20% compared to the first half, laying the foundation for continued quarterly growth in 2027. Concerns about the semiconductor industry cycle peaking are intensifying, and AI demand is showing significant fluctuations **Top Gainers in Pre-Market Trading of US Stocks** Fengzhong Global rose 334.04% in pre-market trading. Based on recent key news: 1. On July 27, Fengzhong Global announced a new product launch, introducing an innovative environmental monitoring device. This device features high precision and low cost, which is expected to significantly enhance the company's competitiveness in the market and drive a substantial increase in stock price. 2. On July 26, the company announced a strategic partnership with a large technology company to jointly develop smart home solutions. This news boosted market confidence in Fengzhong Global's future growth potential, further driving up the stock price. 3. On July 25, Fengzhong Global reported strong quarterly earnings, showing revenue and profit exceeding market expectations. The earnings report indicated significant growth in multiple business areas, uplifting investor sentiment and leading to a substantial increase in stock price. The technology sector has recently performed strongly, with noticeable capital inflows. Weibasi rose 304.33% in pre-market trading. Based on recent key news: 1. On July 30, Wetour Robotics announced a stock consolidation plan with a ratio of 1 to 100. This move may lead to a reevaluation of the company's stock by the market, causing stock price fluctuations. Source: Company announcement 2. On July 29, Fermi and Galaxy Digital faced challenges amid changes in cryptocurrency regulation, leading to fluctuations in investor interest in risk assets. This uncertainty may affect market sentiment. Source: Market observation 3. On July 29, Teucrium Wheat Fund and Sprott Physical Silver Trust showed mixed performance under geopolitical tensions and inflation expectations, reflecting the market's complex response to traditional commodities. Source: Market observation Replimune rose 129.69% in pre-market trading. Based on recent key news: 1. On July 31, an FDA advisory panel supported the trial results of Replimune's RP1 drug, leading to a significant increase in stock price. This drug is used for the treatment of advanced melanoma, and the FDA is expected to make a decision on August 2. Source: Reuters 2. On July 28, FDA staff raised concerns about Replimune's RP1 drug trial, causing the stock price to drop. Review documents indicated a lack of sufficient evidence to prove the drug's efficacy. Source: Reuters 3. On July 30, Replimune announced favorable results from the FDA advisory committee meeting regarding the RP1 drug, with market expectations for accelerated approval nearly certain, leading to a rebound in stock price. Source: Reuters The biopharmaceutical industry faces regulatory challenges, increasing volatility ### Related Stocks - [LIN.US](https://longbridge.com/en/quote/LIN.US.md) - [KLAC.US](https://longbridge.com/en/quote/KLAC.US.md) - [FCUV.US](https://longbridge.com/en/quote/FCUV.US.md) - [WETO.US](https://longbridge.com/en/quote/WETO.US.md) - [REPL.US](https://longbridge.com/en/quote/REPL.US.md) ## Related News & Research - [KLA Corp. Stock Outperforms Competitors Despite Losses On The Day](https://longbridge.com/en/news/295447590.md) - [Wealth Science Advisors LLC Boosts Position in Linde PLC $LIN](https://longbridge.com/en/news/295322495.md) - [Here's How Much $1000 Invested In KLA 20 Years Ago Would Be Worth Today](https://longbridge.com/en/news/294556226.md) - [AI Infrastructure Stocks Riding The Data Center Spending Wave](https://longbridge.com/en/news/294987008.md) - [Linde (NASDAQ:LIN) Updates Q3 2026 Earnings Guidance](https://longbridge.com/en/news/294504010.md)